ENDRA Life Sciences (NASDAQ:NDRA – Get Free Report) and Sight Sciences (NASDAQ:SGHT – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, earnings, institutional ownership, profitability, risk, dividends and analyst recommendations.
Earnings & Valuation
This table compares ENDRA Life Sciences and Sight Sciences”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| ENDRA Life Sciences | N/A | N/A | -$7.03 million | ($8.15) | -0.61 |
| Sight Sciences | $77.36 million | 3.54 | -$38.43 million | ($0.71) | -7.08 |
Analyst Recommendations
This is a summary of current ratings and recommmendations for ENDRA Life Sciences and Sight Sciences, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| ENDRA Life Sciences | 1 | 0 | 1 | 0 | 2.00 |
| Sight Sciences | 1 | 3 | 5 | 0 | 2.44 |
ENDRA Life Sciences currently has a consensus target price of $25.00, suggesting a potential upside of 401.00%. Sight Sciences has a consensus target price of $8.25, suggesting a potential upside of 64.02%. Given ENDRA Life Sciences’ higher possible upside, equities analysts clearly believe ENDRA Life Sciences is more favorable than Sight Sciences.
Profitability
This table compares ENDRA Life Sciences and Sight Sciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| ENDRA Life Sciences | N/A | -433.64% | -204.58% |
| Sight Sciences | -46.83% | -52.34% | -28.49% |
Insider and Institutional Ownership
1.2% of ENDRA Life Sciences shares are held by institutional investors. Comparatively, 55.5% of Sight Sciences shares are held by institutional investors. 10.0% of ENDRA Life Sciences shares are held by insiders. Comparatively, 30.4% of Sight Sciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Volatility & Risk
ENDRA Life Sciences has a beta of -0.06, suggesting that its share price is 106% less volatile than the S&P 500. Comparatively, Sight Sciences has a beta of 2.38, suggesting that its share price is 138% more volatile than the S&P 500.
Summary
Sight Sciences beats ENDRA Life Sciences on 9 of the 13 factors compared between the two stocks.
About ENDRA Life Sciences
ENDRA Life Sciences Inc. develops technologies to improve the capabilities of clinical diagnostic ultrasound. The company is developing thermo-acoustic enhanced ultrasound technology that uses radio frequency pulses to generate ultrasonic waves in tissue to create high-contrast images for use in the treatment of nonalcoholic fatty liver disease, as well as in tissue composition, temperature monitoring, vascular imaging, and tissue perfusion. It has a collaborative research agreement with General Electric Company. ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan.
About Sight Sciences
Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. It also offers TearCare System, a wearable eyelid technology for adult patients with evaporative dry eye disease due to meibomian gland dysfunction, as well as related components. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. Sight Sciences, Inc. was incorporated in 2010 and is headquartered in Menlo Park, California.
Receive News & Ratings for ENDRA Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ENDRA Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
